Checkpoint Therapeutics (stock ticker: CKPT) is a biopharmaceutical company that works in the oncology field. Checkpoint acquires, develops, and commercializes immune-enhanced combination treatments for solid tumor cancers. Checkpoint has two leading drug candidates in development.
CK-101, known as cosibelimab, is a small-molecule targeted anti-cancer agent, currently undergoing a Phase 1/2 clinical study for the treatment of specific non-small cell lung cancer (NSCLC). The drug has shown promise compared to traditional chemotherapy treatments.
The second candidate, CK-301, is an antibody drug currently in a Phase 1 clinical trial focused on patients with selected recurrent or metastatic cancers. The selected cancers include NSCLC, as well as metastatic melanoma, renal cell carcinoma, head and neck cancer, and urothelial carcinoma.
CK-301 has shown a 44% objective response rate in treated patients during the Phase 1 study, along with a 10.3-month median progression-free survival rate, when compared to currently available approved treatments. Based on these results, the company is continuing its clinical phase program, including an early registration of patients for a Phase 3 study.
Among the fans is Cantor analyst Jennifer Kim who writes, “We think the risk-reward is favorable”. The analyst added: “The potential peak sales opportunity for cosibelimab is underappreciated, in our view, and we expect upwards earnings estimate revisions to drive CKPT shares higher.”
In line with her upbeat outlook she has $16 price for the stock which indicates confidence in a 331% upside potential for the stock.
Turning now to the rest of the Street, other analysts are on the same page. With only Buys assigned in the last three months, 3 to be exact, the word on the Street is that CKPT is a Strong Buy.
Want to receive the latest stock and cryptocurrency news and investing ideas that can help you make money ?! Subscribe to our newsletter. Enter your email below and hit the subscribe button.
If you want to start investing in stocks click on the banner below and invest with our trusted partner eToro:
If you want professional consultation regarding stock or cryptocurrency investing leave your information below and experts from our trusted partners will reach out to you